MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Schrodinger Inc

Gesloten

SectorGezondheidszorg

19.9 5.68

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.51

Max

20.19

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.1M

-40M

Verkoop

53M

88M

EPS

-0.24

Winstmarge

-45.536

Werknemers

891

EBITDA

48M

-19M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+67.89% upside

Dividenden

By Dow Jones

Volgende Winsten

30 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-122M

1.5B

Vorige openingsprijs

14.22

Vorige sluitingsprijs

19.9

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2024, 11:55 UTC

Top Nieuws

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

67.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.63 USD  67.89%

Hoogste 45 USD

Laagste 27 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technische score

By Trading Central

19.75 / 19.92Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.